PHARMACY

Study: Pharmaceutical companies lag in Hispanic-targeted ad spending

BY Antoinette Alexander

FAIRFAX, Va. — According to a new report from national trade organization AHAA: the Voice of Hispanic Marketing, pharmaceutical marketers have room for improvement when it comes to Hispanic advertising.

According to AHAA, pharmaceutical marketers increased their aggregate Hispanic advertising investment by only 4% between 2010 and 2014 to $165 million. Among the top 500 U.S. advertisers, the pharmaceutical category allocation to Hispanic dedicated media remained basically unchanged at 2.5%, which is significantly less than the national average of 8.5%.

Despite research supporting the importance of the Hispanic market to corporate bottom lines, the average Hispanic ad spend by pharmaceutical companies decreased 9% from $6.9 million to $6.3 million in 2014. According to the organization, this category remains at a "laggard" allocation level, defined as companies who assign 1% to 3.5% of their marketing budget to Hispanic dedicated efforts.

Over the past five years, the top 500 advertisers boosted their spending in Hispanic-targeted media by 63% or $2.7 billion from $4.3 billion in 2010 to $7.1 billion. The top 500 advertisers boosted their average spending from $9 million in Hispanic-targeted media in 2010 to today's $14 million.

Data was collected from Nielsen Monitor Plus, which tracked more than 340,000 companies' advertising expenditures in English and Spanish. This data was analyzed by Santiago Solutions Group for AHAA. SSG divided companies into five tiers according to the percent allocation to Spanish/Bilingual media: Best-in-Class (more than 14.2%), Leaders (6.4%-14.2%), Followers (3.6%-6.3%), Laggards (1%-3.5%), and On the Sidelines (Less than 1%).

SSG also segmented the Top 500 overall spending (English + Spanish) companies for years 2010 to 2014, thus permitting the analysis of trends in the marketplace. Ad spend Includes spending in Network TV, Spot TV, Cable TV, radio, magazines, newspaper and FSIs. It excludes B2B, display, outdoor and cinema.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Report: Medicare Part D plans less apt to cover opioids with abuse deterrents

BY DSN STAFF

Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility. In particular, the research shows that Medicare Part D plans cover generic opioids that lack abuse-deterrent features at a higher rate than it covers branded opioids. 
 
“While there has been significant attention on the development and approval of new abuse-deterrent drug products, there has been noticeably less consideration of access to such products,” Avalere CEO Dan Mendelson said.
 
Particularly with regard to oxycodone hydrochloride, the brand-name OxyContin received approval from the Food and Drug Administration in 2013 for abuse-deterrent labeling, but since 2012, Part D plan coverage for it has dropped from 61% to 46%. On the other hand, every Part D plan covers generic oxycodone hydrochloride. As a result, seniors have less access to safer opioids.
 
“While prescription opioid abuse continues to be a priority for public health experts and lawmakers, coverage for these products by Part D plans is limited and plans are increasingly favoring lower-cost generic products on their formularies,” Avalere SVP Caroline Pearson said. “Policymakers seeking to limit opioid abuse will have to balance the desire for greater access to abuse-deterrent opioids with the increased costs of such medications to public programs and private payers.”
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Report: Florida Board of Pharmacy holds public hearing on patient access to pain meds

BY Antoinette Alexander

TAMPA, Fla. — Patient access to medically necessary pain medications and prescription drug abuse is a complex issue that has many pharmacists caught in the middle. In an effort to find a resolution, patients impacted by the debacle convened for a public hearing Tuesday to share their stories before the Florida Board of Pharmacy, according to a local news report.

The hearing marked the first time that patients got the chance to share their stories of frustration and humiliation when trying to fill legitimate prescriptions.

Doctors and pharmacists also addressed the Florida Board of Pharmacy Committee, according to WFTS-TV. Also in attendance was Kevin Nicholson, VP, public policy and regulatory affairs of the National Association of Chain Drug Stores, who spoke briefly at the hearing.

After hearing public comment, the committee began brainstorming for resolutions. According to the report, they include better communication between the pharmacists and physicians and a reevaluation of the red flag system.

Click here to view the full report on the "pharmacy crawl."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?